Research programme: receptor tyrosine kinase targeting monoclonal antibodies - Celldex Therapeutics

Drug Profile

Research programme: receptor tyrosine kinase targeting monoclonal antibodies - Celldex Therapeutics

Alternative Names: ALK-ADC; Anti-MET antibodies - Celldex; Anti-MET humanised monoclonal antibody - Celldex; KTN-0073; KTN-0125; KTN0125-TEI; KTN0216

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kolltan Pharmaceuticals
  • Developer Celldex Therapeutics Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto oncogene protein c met inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Neuroblastoma

Most Recent Events

  • 10 Nov 2018 Pharmacodynamics data from a preclinical trial in Cancer released by Celldex
  • 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
  • 19 Apr 2016 Preclinical trials in Neuroblastoma in USA (Parenteral) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top